Spectrum Equity's Steve LeSieur and Jeff Haywood Named 2024 Top GrowthCap Healthcare Investors

Spectrum Equity's Jeff Haywood and Steve LeSieur have been named #3 on GrowthCap's overall top health investors for 2024.

To be selected, nominees must demonstrate expertise and success investing in healthcare, whether in healthcare software, healthcare services, medical technologies, biotechnology, the connected patient experience, or other related areas. In addition, selected nominees provide unique strategic and/or operational value to the companies they invest in and have earned the respect of their peers in the industry.

Jeff Haywood and Steve LeSieur have been co-heads of Spectrum Equity’s healthcare investments since 2015. The firm’s healthcare efforts are focused on high growth internet-enabled software and data services companies serving all parts of the healthcare continuum.

Jeff currently serves on the boards of Definitive Healthcare (NASDAQ: DH), RxVantage, Membersy and Datassential. He also led Spectrum’s investment in PWNHealth and subsequent sale to Everlywell, where he continues as a board observer. Jeff was previously involved with GoodRx (NASDAQ: GDRX), Payer Compass (acquired by Zelis Healthcare), Net Health (acquired by The Carlyle Group), Verisys (acquired by Aperture Health), Passport Health Communications (acquired by Experian), and MedHOK (acquired by Hearst Health).

Steve LeSieur is co-head of Spectrum Equity’s investing efforts across healthcare, which he has co-led with Jeff Haywood since 2015.

Steve recently served on the board of GoodRx (NASDAQ: GDRX) and was previously involved with Payer Compass (acquired by Zelis Healthcare), Definitive Healthcare (NASDAQ:DH), MedHOK (acquired by Hearst Health), HealthMEDX (acquired by NetSmart), Passport Health Communications (acquired by Experian) and QTC Management (acquired by Lockheed Martin).

Read more about Jeff, Steve, and their fellow honorees here.

Recognition presented herein are from third parties that are not affiliated with Spectrum Equity, and these third parties independently assess nominees based on based on multiple criteria. Spectrum Equity submitted the nominations to be considered for the GrowthCap Top 40 Under 40 award and has paid a fee to promote/distribute this award after designation was announced. Past performance and such ranking are not a guarantee of future results. There is no guarantee that other designations or rankings would reach the same conclusions. An award may not be representative of a particular investor’s return.

The specific companies identified above do not represent all of Spectrum’s investments, and no assumptions should be made that any investments identified were or will be profitable. View the complete list of our portfolio companies. Spectrum is not responsible for the contents of any third party website linked above, and has not confirmed the accuracy of any information provided therein.